11 results
Objective PrimaryDose escalation phase only: To determine the MTD of HCD122 when administered in combination with bendamustineDose expansion phase only: To assess the safety and tolerability of HCD122 in combination with bendamustine SecondaryDose…
We aim to to record heart rate patterns during seizures with miniaturized wearable EKG-monitors in a large cohort of DS
To define and evaluate OCT stent guidance parameters through prospective data collection in PCI procedures of de novo lesions.
Primary Objective: To demonstrate the safety and efficacy of an OCT guided strategy for stent implantation.Trial Hypothesis: OCT-guided stent placement with application of a novel algorithm is non-inferior to IVUS-guided stent placement and superior…
The primary objective for this study is as follows:* To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used incombination with bendamustine compared with bendamustine alone in patients with indolentNHL refractory to…
Primary: - To evaluate differences in side effect profile of patients treated with focal or extended ablation performed with image-guided IRE for the ablation of prostate carcinoma. - To evaluate differences in quality of life of patients treated…
The objective of the study is to investigate the feasibility and efficacy of treatment with lenalidomide and rituximab with or without bendamustine in patients with relapsed follicular lymphoma.
The primary objectives of the Phase Ib portion of the study are as follows:* To assess the safety and tolerability of the combination of polatuzumab vedotin with bendamustine and rituximab (BR) or bendamustine and obinutuzumab (BG) when administered…
Primary Objectives- Determine the MTD of pixantrone, rituximab (only in CD20 positive tumors), etoposide, and bendamustine in *fit' patients with rel aNHL of B- or T-cell phenotype.- Evaluate the ORR and PFS using the combination of pixantrone…
Efficacy ObjectivesThe primary efficacy objective:• To evaluate the efficacy of GDC-0199 and rituximab (GDC-0199+R) compared with bendamustine and rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) as measured…
Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)